Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


11 agosto 2017

Philips completes acquisition of Spectranetics

Interventional News

Philips has announced that it has completed the acquisition of The Spectranetics Corporation, a US-based global leader in vascular intervention and lead management solutions. Spectranetics’ financial results will be consolidated as part of Philips’ Image-Guided Therapy business group as of 9 August 2017.

28 junio 2017

Philips sets sights on Spectranetics, also acquires CardioProlific

Interventional News

Royal Philips and The Spectranetics Corporation announced that they have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for US$38.50 per share, to be paid in cash upon completion.

21 julio 2017

SIR issues position statement encouraging paid parental leave

Interventional News

The Society of Interventional Radiology and its Women in Interventional Radiology section have issued a position statement to support interventional radiologists who choose to become parents. The statement was published in the July issue of SIR’s Journal of Vascular and Interventional Radiology (JVIR).

23 mayo 2017

New data show SIRT does not prolong overall survival in metastatic colorectal cancer patients

Interventional News

The FOXFIRE, SIRFLOX and FOXFIRE Global randomised studies evaluated the efficacy of combining first-line chemotherapy for metastatic colorectal cancer with selective internal radiotherapy (SIRT) using yttrium-90 resin microspheres (SIR-Spheres, Sirtex) in patients with liver metastases. The combined FOXFIRE analysis comprises data from the SIRFLOX study, first presented in 2015, and data from two new studies – FOXFIRE and FOXFIRE Global.

27 julio 2017

Spectranetics announces FDA approval of Stellarex drug-coated balloon

Interventional News

Spectranetics has announced receipt of US Food and Drug Administration (FDA) premarket approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral artery disease (PAD).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.